ArticleEnvironmental health perspectives1994
Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
Article in Environmental health perspectives, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Polymorphisms in GSTT1 and GSTM1 genes as possible risk factors for susceptibility to breast cancer development and their influence in chemotherapy response: a systematic review.Molecular biology reports · 2020Pooled it
- CYP2D6*4 allele polymorphism increases the risk of Parkinson's disease: evidence from meta-analysis.PloS one · 2013Pooled it
- Faecal Metabolome Profiles in Individuals Diagnosed with Hyperplastic Polyps and Conventional Adenomas.International journal of molecular sciences · 2024Article
- Article
- Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2013Article
- The Upper Midwest Health Study: gliomas and occupational exposure to chlorinated solvents.Occupational and environmental medicine · 2013Article
- Review of studies on metabolic genes and cancer in populations of African descent.Genetics in medicine : official journal of the American College of Medical Genetics · 2010Review
- Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers.Environmental health perspectives · 2006Article
- Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.The pharmacogenomics journal · 2004Review
- Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.British journal of clinical pharmacology · 2003Article
- Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma.British journal of cancer · 2000Article
- Tobacco smoke: chemical carcinogenesis and genetic lesions.Ochsner journal · 1999Article
- Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity.Environmental health perspectives · 1997Review
- Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer.Environmental health perspectives · 1996Article
- An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.Human genetics · 1996Article
- Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.Annals of the rheumatic diseases · 1996Article
- Molecular basis of polymorphic drug metabolism.Journal of molecular medicine (Berlin, Germany) · 1995Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymorphisms in many xenobiotic metabolizing enzymes occur leading to variation in the level of enzyme expression in vivo. Enzymes showing such polymorphisms include the cytochrome P450 enzymes CYP1A1, CYP1A2, CYP2A6, CYP2D6, and CYP2E1 and the phase two metabolism enzymes glutathione S-transferase MI (GSTMI) and arylamine N-acetyltransferase 2 (NAT2). In the past, these polymorphisms have been studied by phenotyping using in vivo administration of probe drugs. However, the mutations which give rise to several of these polymorphisms have now been identified and genotyping assays for polymorphisms in CYP1A1, CYP2A6, CYP2D6, CYP2E1, GSTMI, and NAT2 have been developed. Specific phenotypes for several of the polymorphic enzymes have been associated with increased susceptibility to malignancy, particularly lung and bladder cancer, and Parkinson's disease. These associations are likely to be due to altered activation or detoxication of chemicals initiating these diseases, including components of tobacco smoke and neurotoxins. The substrate specificity and tissue distribution of polymorphic enzymes implicated in disease causation discussed with particular reference to previously described disease-phenotype associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.